Tim Van Hauwermeiren, argenx CEO
June 21, 2024 05:02 PM EDTUpdated June 24, 09:05 AM
Pharma
FDA+

Ar­genx wins sec­ond FDA ap­proval for Vyv­gart in au­toim­mune nerve dis­ease

Ryan Cross

Senior Science Correspondent

Af­ter a string of clin­i­cal fail­ures, the Dutch biotech ar­genx land­ed a much-need­ed win on Fri­day when the FDA ap­proved its au­toim­mune dis­ease drug, Vyv­gart …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times